Pre-profitability the company was going to be the initial leader in opioid deterrent technology, which had the potential of a much larger revenue than what we’re doing today. Adderall ER was last decent drug and it was basically a failure to launch and that was almost 3 years ago. Pipeline & R&D has been stalled since then due to pandemic, but shares to CEO were not. $12M drugs continue to have Elite limp along and we can always continue the ANDA sell off strategy.
News 
Market Data 
Discover 
